Tenapanor
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Irritable Bowel Syndrome With Constipation (IBS-C)
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Trial Timeline
Feb 17, 2023 → Oct 1, 2031
NCT ID
NCT05905926About Tenapanor
Tenapanor is a phase 3 stage product being developed by Ardelyx for Irritable Bowel Syndrome With Constipation (IBS-C). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05905926. Target conditions include Irritable Bowel Syndrome With Constipation (IBS-C).
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06810167 | Phase 3 | Recruiting |
| NCT05995899 | Approved | Completed |
| NCT06203444 | Phase 1 | Completed |
| NCT05905926 | Phase 3 | Recruiting |
| NCT04549597 | Approved | Completed |
| NCT02727751 | Phase 3 | Completed |
Competing Products
20 competing products in Irritable Bowel Syndrome With Constipation (IBS-C)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linaclotide + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| YM060 + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| linaclotide + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron | Astellas Pharma | Pre-clinical | 23 |
| YM060 | Astellas Pharma | Phase 2 | 52 |
| ONO-2952 + Placebo comparator | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2952 + ONO-2952 Matching Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| duloxetine | Eli Lilly | Approved | 85 |
| Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | AbbVie | Phase 3 | 77 |
| 25mg Eluxadoline + 100mg Eluxadoline | AbbVie | Phase 3 | 77 |
| Eluxadoline + Placebo | AbbVie | Phase 2 | 52 |
| Placebo + Linaclotide | AstraZeneca | Phase 3 | 77 |
| Tegaserod | Novartis | Pre-clinical | 23 |
| DNK333 | Novartis | Phase 2 | 52 |
| SMS995 + Placebo | Novartis | Phase 1 | 33 |